40914-13-4Relevant articles and documents
Synthesis, characterization and evaluation of novel ferrocenylmethylamine derivatives as cytotoxic agents
Savani, Chirag J.,Roy, Hetal,Verma, Sanjay K.,Vennapu, Dushyanth R.,Singh, Vinay K.
, (2021/01/12)
The present report describes a new series of amide functionalized 20- and 30-aminomethylferrocene derived from ferrocenylmethylamine. The compounds 1a-5a and 1b-5b were characterized by microanalysis, 1H, 13C NMR, UV–visible, fluorescence, FTIR, thermogravimetric and crystallographic techniques. The X-ray analysis demonstrated the ability of these molecules to form various intermolecular hydrogen bonding interactions, as verified by Hirshfeld surface analysis. All the compounds were evaluated against MCF 7, IMR 32, HepG2 and immortal L132 cell lines by MTT assay and the results were compared with cisplatin. Interestingly, many compounds were very active against all the investigated cell lines and proved to be more potent as cytotoxic agents than cisplatin. The western blot, gene expression, mitochondrial membrane potential and flow cytometry study were used to investigate the mode of action of these derivatives as antitumor agents. The results showed apoptotic property of the compounds by modulating inflammatory pathway against human tumor cells of different origin. We performed the density functional theory calculations and molecular docking to rationalize the experimental results.
Curcumenol derivatives and application of curcumenol derivatives in preparing antitumor drug
-
Paragraph 0033; 0034; 0036, (2018/04/03)
The invention relates to curcumenol derivatives and application of the curcumenol derivatives in preparing an antitumor drug. By performing structure modification on the curcumenol derivatives, aftera furfuryl amine fragment is introduced at a hydroxy group site of curcumenol, amine is further introduced through Mannich reaction to obtain a series of the curcumenol derivatives of a structure of aformula (I) as well as pharmaceutically acceptable salts, hydrates, solvates or prodrugs of the curcumenol derivatives which are not reported. Verified by an in vitro bioactivity experiment, the newcurcumenol derivatives have the inhibitory activity to a cervical cancer, a liver cancer, a lung cancer and the like, and the compound activity of most of the new curcumenol derivatives are remarkablyhigher than that of curcumenol as a parent of the new curcumenol derivatives. In addition, the polarity of the vast majority of the synthesized curcumenol derivatives is remarkably improved comparedwith the curcumenol; according to the similarity and intermiscibility principle, the phenomenon that the solubility of the synthesized curcumenol derivatives is higher than that of the curcumenol of aparent compound is proved to a certain degree, and a basic theoretical basis is provided for better performing preparation research and exerting efficacy. The formula (I) is shown in the description.
Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors
Bodill, Taryn,Conibear, Anne C.,Mutorwa, Marius K.M.,Goble, Jessica L.,Blatch, Gregory L.,Lobb, Kevin A.,Klein, Rosalyn,Kaye, Perry T.
, p. 4332 - 4341 (2013/07/27)
DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions.
